Oct 19, 2026 8:05am EDT Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Aug 13, 2026 8:05am EDT Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Jul 28, 2026 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
May 21, 2026 5:17pm EDT Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 14, 2026 8:05am EDT Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
